Cipher Pharmaceuticals Inc. (CPHRF)

Market Cap	150.14M
Revenue (ttm)	21.30M
Net Income (ttm)	20.38M
Shares Out	24.02M
EPS (ttm)	0.82
PE Ratio	7.62
Forward PE	13.75
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,875
Open	6.30
Previous Close	6.30
Day's Range	6.25 - 6.30
52-Week Range	2.20 - 7.37
Beta	1.04
Analysts	Buy
Price Target	4.75 (-24.0%)
Earnings Date	n/a

About CPHRF

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwante...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 6
• Stock Exchange: OTCMKTS
• Ticker Symbol: CPHRF

Financial Performance

In 2023, CPHRF's revenue was $21.55 million, an increase of 4.23% compared to the previous year's $20.68 million. Earnings were $20.38 million, a decrease of -23.48%.

Financial numbers in USD

Analyst Forecast

According to one analyst, the rating for CPHRF stock is "Buy" and the 12-month stock price forecast is $4.75.

Price Target

$4.75

(-24.00% downside)

Analyst Consensus: Buy